Medications for Opioid Use Disorder During the Prenatal Period and Infant Outcomes

Mir M Ali; Kristina D West; Rachel Mosher Henke; Michael A Head; Stephen W Patrick

doi:10.1001/jamapediatrics.2023.3072

Medications for Opioid Use Disorder During the Prenatal Period and Infant Outcomes

JAMA Pediatr. 2023 Nov 1;177(11):1228-1230. doi: 10.1001/jamapediatrics.2023.3072.

Authors

Mir M Ali¹, Kristina D West¹, Rachel Mosher Henke², Michael A Head³, Stephen W Patrick⁴

Affiliations

¹ Office of the Assistant Secretary for Planning and Evaluation, US Department of Health and Human Services, Washington, DC.
² Lewin Group.
³ IBM Consulting.
⁴ Vanderbilt Center for Child Health Policy, Departments of Pediatrics and Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.

No abstract available

Plain language summary

This cross-sectional study explores the association between mothers’ receipt of opioid use disorder treatment during pregnancy and their infants’ health services use in the first year of life.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Female
Humans
Infant
Mothers*
Opioid-Related Disorders*
Pregnancy

Grants and funding

P50 HD103537/HD/NICHD NIH HHS/United States